Company Profiles

driven by the PitchBook Platform

Amal Therapeutics

Description

Developer of therapeutic cancer vaccines. The company develops and progresses therapeutic cancer vaccines and therapeutic tumor vaccination.

2012

Founded

PRIVATE

Status

1-10

Employees

Series A

Latest Deal Type

$3.05M

Latest Deal Amount

$3.16M

Total Amount Raised

Description

Developer of therapeutic cancer vaccines. The company develops and progresses therapeutic cancer vaccines and therapeutic tumor vaccination.

Website:

www.amaltherapeutics.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

c/o Fondation pour Recherches Médicales 64 av. de la Roseraie 1205 GenevaSwitzerland
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Amal Therapeutics's full profile, request a free trial.

Amal Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Amal Therapeutics Investors (5)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Boehringer Ingelheim Venture FundCorporate Venture CapitalMinority000 0000000 0000
Commission for Technology and InnovationGovernment000 0000000 0000
High-Tech GründerfondsVenture CapitalMinority000 0000000 0000
Venture kickAccelerator/IncubatorMinority000 0000000 0000
VI PartnersVenture CapitalMinority000 0000000 0000
Boehringer Ingelheim Venture Fund Corporate Venture Capital
Commission for Technology and Innovation Government
High-Tech Gründerfonds Venture Capital
Venture kick Accelerator/Incubator
VI Partners Venture Capital

Amal Therapeutics Executive Team (1)

NameTitleBoard
Seat
Contact
Info
Madiha Derouazi Ph.DFounder & Chief Executive Officer
Madiha Derouazi Ph.D Founder & Chief Executive Officer

Amal Therapeutics Board Members (5)

NameRepresentingRoleSinceContact
Info
Diego Braguglia Ph.DVI PartnersGeneral Partner000 0000
Frank Hensel Ph.DHigh-Tech GründerfondsSenior Investment Manager000 0000
Frank Kalkbrenner MDBoehringer IngelheimBoard Observer000 0000
Johanna Holldack MDSelfChairman000 0000
Knut Elbers Ph.DBoehringer IngelheimDirector, Project Manager & Investment Manager000 0000
Diego Braguglia Ph.D General Partner VI Partners
Frank Hensel Ph.D Senior Investment Manager High-Tech Gründerfonds
Frank Kalkbrenner MD Board Observer Boehringer Ingelheim
Johanna Holldack MD Chairman Self
Knut Elbers Ph.D Director, Project Manager & Investment Manager Boehringer Ingelheim
Request full access to PitchBook